Region:Middle East
Author(s):Shubham
Product Code:KRAD6690
Pages:80
Published On:December 2025

By Product Type:The product type segmentation includes various categories of deep brain stimulators and their accessories. The market is characterized by a diverse range of products, with dual-channel deep brain stimulators leading the way due to their advanced capabilities, ability to stimulate bilateral targets, and strong clinical evidence for improving Parkinson's disease motor symptoms. Single-channel stimulators and accessories also play significant roles, catering to specific patient needs, device replacement cycles, and hospital procurement preferences.

By Target Indication (DBS in Parkinson’s Disease):The target indication segmentation focuses on the specific types of Parkinson's disease that deep brain stimulation addresses. Tremor-dominant Parkinson's disease is a major indication for DBS, as the therapy is particularly effective for medication-refractory tremor and motor fluctuations, which supports strong demand for surgical intervention. Akinetic-rigid and mixed-type Parkinson's disease also contribute significantly to the market, as they require tailored programming strategies and long-term neurology follow-up to optimize symptom control.

The UAE Deep Brain Stimulation Parkinson's Disease Market is characterized by a dynamic mix of regional and international players. Leading participants such as Medtronic plc, Boston Scientific Corporation, Abbott Laboratories (Abbott Neuromodulation), Aleva Neurotherapeutics SA, Beijing PINS Medical Co., Ltd., SceneRay Co., Ltd., LivaNova PLC, Functional Neuromodulation Ltd., Nevro Corp, NeuroPace, Inc., National Neuroscience Institute – King Faisal Specialist Hospital & Research Centre (regional reference center), Cleveland Clinic Abu Dhabi – Neurological Institute, Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, Rashid Hospital & Dubai Health (Dubai Academic Health Corporation), Mediclinic City Hospital, Dubai contribute to innovation, geographic expansion, and service delivery in this space.
The future of the UAE Deep Brain Stimulation market appears promising, driven by ongoing advancements in technology and increasing healthcare investments. As the government prioritizes neurological health, initiatives to enhance healthcare infrastructure are expected to facilitate better access to DBS treatments. Furthermore, the integration of telemedicine and AI in treatment planning will likely improve patient outcomes and streamline processes, making DBS more accessible and effective for those suffering from Parkinson's disease.
| Segment | Sub-Segments |
|---|---|
| By Product Type | Dual-channel Deep Brain Stimulators Single-channel Deep Brain Stimulators Accessories (leads, extensions, programmers) Others |
| By Target Indication (DBS in Parkinson’s Disease) | Tremor-dominant Parkinson’s Disease Akinetic-rigid Parkinson’s Disease Mixed-type Parkinson’s Disease Others |
| By Surgical Approach | Frame-based Stereotactic DBS Frameless / Image-guided DBS Robot-assisted DBS Others |
| By Stimulation Mode | Conventional Continuous Stimulation Directional / Current-steering Stimulation Adaptive / Closed-loop Stimulation Others |
| By End-User | Tertiary Care Hospitals Specialized Neuroscience & Movement Disorder Centers Academic & Research Institutions Others |
| By Payer Type | Government & Public Insurance Private Health Insurance Self-pay / Out-of-pocket Others |
| By Emirate | Abu Dhabi Dubai Sharjah & Northern Emirates Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Neurology Clinics | 100 | Neurologists, Clinic Managers |
| Hospitals Performing DBS | 80 | Neurosurgeons, Hospital Administrators |
| Patient Support Groups | 60 | Patients, Caregivers |
| Healthcare Policy Makers | 50 | Health Ministry Officials, Policy Analysts |
| Medical Device Suppliers | 70 | Sales Representatives, Product Managers |
The UAE Deep Brain Stimulation market for Parkinson's disease is valued at approximately USD 130 million, reflecting the increasing prevalence of the condition and advancements in treatment technologies.